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BACKGROUND: The serum proteomic test VeriStrat has been shown to be able to classify advanced non-small cell lung cancer
(NSCLC) patients for overall survival (OS) after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs). In this study, VeriStrat was evaluated as a pre-treatment stratification tool in patients with advanced stage NSCLC for
treatment with the combination of erlotinib and sorafenib, considering both OS and progression-free survival (PFS) as end points.
METHODS: Serum samples from 50 patients treated within the context of a phase II trial of first-line erlotinib and sorafenib were
analysed with VeriStrat, a fully locked mass spectrometry-based test that identifies patients likely to have good or poor outcome on
EGFR therapy based on eight distinct features in mass spectra. Analysis was performed fully blinded to all clinical data, and then the
outcome data were analysed with respect to the obtained serum classifications.
RESULTS: VeriStrat classified pre-treatment samples into two groups, VeriStrat Good and VeriStrat Poor, which were significantly
different in OS (hazard ratio (HR) 0.30, log-rank P¼ 0.009) and in PFS (HR 0.40, log-rank P¼ 0.035).
CONCLUSION: VeriStrat has shown its potential for stratification of unselected, advanced stage NSCLC patients treated in first line with
a combination of erlotinib and sorafenib.
British Journal of Cancer (2012) 107, 1820–1825. doi:10.1038/bjc.2012.470 www.bjcancer.com
Published online 18 October 2012
& 2012 Cancer Research UK
Keywords: lung cancer; proteomics; erlotinib; sorafenib; serum biomarker; personalised therapy



















































The epidermal growth factor receptor (EGFR) family is an
important target in the treatment of non-small cell lung cancer
(NSCLC). Inhibition of the EGFR pathway with tyrosine kinase
inhibitors (TKIs), such as erlotinib in patients with advanced
NSCLC, leads to improved survival compared with placebo
(Shepherd et al, 2005). Another area of investigation has been
the vascular endothelial growth factor (VEGF) pathway, which has
a crucial role in initiation of angiogenesis (Herbst et al, 2005).
When both pathways are inhibited simultaneously, the effect may
be synergistic (Camp et al, 2005; Herbst et al, 2005). Indeed,
treatment with an EGFR-TKI and a VEGF receptor inhibitor
showed improved response rates and progression-free survival
(PFS) as compared with EGFR-TKI mono-therapy; however, so far
this combination treatment has not demonstrated a survival
benefit and showed disappointing results in an unselected patient
population in first-line setting (Dingemans et al, 2011; Herbst et al,
2011). Hence, a reliable biomarker that predicts clinical benefit of
combined EGFR-VEGF inhibition would be very helpful in guiding
patient selection, as of today EGFR mutations are the sole validated
predictive biomarkers for patient selection for treatment with
single-agent EGFR-TKIs (Sequist et al, 2007). Matrix-assisted
laser desorption/ionisation time-of-flight (MALDI-TOF) mass
spectrometry (MS) is a technique for analysing biological samples,
such as plasma, urine and tissue, by characterising protein content
through peaks in the mass spectrum (Yanagisawa et al, 2003).
VeriStrat (Biodesix, Boulder, CO, USA) is a test based on a
MALDI-TOF MS signature of eight protein or peptide features. It
was developed using pre-treatment serum samples from a cohort
of advanced NSCLC patients that experienced long-term stable
disease vs early progression on gefitinib monotherapy. From the
mass spectra of these serum samples, eight MS features
differentiating the two outcome groups were identified and used
to develop the VeriStrat classifier. This classifier assigns a
classification to each new serum sample: VeriStrat Good (‘good’)
or VeriStrat Poor (‘poor’). In less than 3% of cases an unequivocal
classification cannot be assigned and the result is reported as
indeterminate. The VeriStrat test was validated in two independent
cohorts of unselected NSCLC patients treated with erlotinib or
gefitinib (Taguchi et al, 2007), which showed that patients with
pre-treatment serum classified as ‘good’ had better overall survival
(OS) than those with serum classified as ‘poor’ after treatment with
EGFR-TKIs (Taguchi et al, 2007). Also, it has been shown to be
able to classify two independent cohorts of first-line patients and
one cohort of second-line patients treated with erlotinib and
bevacizumab (a VEGF receptor inhibitor) into groups with better
or worse OS (Akerley et al, 2010; Carbone et al, 2010b; Gautschi
et al, 2012). Newer oral VEGF receptor inhibitors (such as
sorafenib) in combination with erlotinib were found to have
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clinically relevant activity in a recent phase II study (Lind et al,
2010). Within the context of this study, it was investigated whether
VeriStrat also differentiates outcome after treatment with erlotinib
and sorafenib in chemotherapy-naive patients with advanced
NSCLC.
MATERIAL AND METHODS
Patients and protocol
Serum samples were collected from chemotherapy-naive patients
(n¼ 50) who were treated with erlotinib and sorafenib in a
multicentre single-arm phase II study (Lind et al, 2010). Inclusion
criteria in this trial were chemotherapy-naive patients with
pathologically documented, inoperable, locally advanced, recur-
rent or metastatic NSCLC. In addition, age X18 year, Eastern
Cooperative Oncology Group performance status 0 or 1, estimated
life expectancy X12 weeks and adequate haematologic, renal and
hepatic function were required for inclusion. Patients had to have
at least one measurable lesion according to the Response
Evaluation Criteria of Solid Tumours (Therasse et al, 2000).
Exclusion criteria included symptomatic brain metastasis, severe
or unstable systemic disease, seizure disorder requiring medica-
tion, history of bleeding diathesis and cardiac disease, and
uncontrolled hypertension. Patients received orally administered
sorafenib 400mg twice a day and erlotinib 150mg once a day. OS
was defined as time from start of treatment to death, irrespective of
cause. PFS was defined as time from start of treatment to
documented progression of disease or death. The study was
approved by the local medical ethical review boards. All patients
provided written informed consent. The study is registered with
ClinicalTrials.gov, number NCT00722969.
Serum samples
Serum samples were collected pre-treatment and at weeks 1 and 3
after treatment initiation. The collection of sera was performed
according to the protocols approved by the local institutional
review board. The sera were allowed to clot for 1 h after which they
were centrifuged at room temperature for 10min at 3000 r.p.m.
Aliquots were taken and stored at  80 1C until further use.
Thawing of aliquots was allowed only once. Serum samples were
sent to Biodesix (Boulder, CO, USA) for VeriStrat testing blinded
to all clinical data. The treating physician was unaware of the
outcome of the VeriStrat testing.
Serum proteomic testing
The sera were diluted 1 : 10 in HPLC-grade water and mixed
(1 : 1 v/v) with matrix solution (25mgml 1 sinapinic acid (Sigma,
St Louis, MO, USA) dissolved in 50 : 50 : 0.1% acetonitrile (Burdick
& Jackson, Muskegon, MI, USA) : water : trifluoroacetic acid
(Sigma)). The serum–matrix mixture was spotted in triplicate on
a MALDI target in randomly assigned plate positions and mass
spectra acquired using an Autoflex MALDI-TOF mass spectro-
meter (Bruker Daltonics, Bremen, Germany). Each replicate
spectrum consisted of an average of 2000 individual spectra
collected from various locations within the spot. Spectral
preprocessing was performed, which included background and
noise estimation, background subtraction, alignment and normal-
isation to partial ion current before spectral analysis by the
VeriStrat algorithm, which classifies each sample as VeriStrat
Good, Poor or Indeterminate. All details of sample processing,
spectral preprocessing and the classification algorithm, based
on eight distinct m/z features have been fixed since develop-
ment of the test in 2006 (Taguchi et al, 2007). The identity
of the proteins that make up the MALDI-MS features used in
the test are still under investigation. VeriStrat classifications
obtained for the samples were returned to the centre curating
the study database, where they were unblinded and merged with
the clinical database.
Statistics
Statistical significance of difference in OS and PFS between groups
was assessed using log-rank P-values. The hazard ratios (HRs)
were calculated using Mantel–Haenszel methods. Categorical data
were compared between patient groups using Fisher’s exact tests.
Analyses were performed using PRISM (Graphpad, La Jolla, CA,
USA) and SAS Enterprise Guide 4.3 (SAS, Cary, NC, USA).
RESULTS
Patient characteristics and pre-treatment VeriStrat
classification
Pre-treatment samples were collected from 50 patients. One sample
was classified as indeterminate and one sample was not available,
due to withdrawal of consent. Thirty-three samples were classified
as ‘good’ and 15 samples as ‘poor’. Distribution of the patient
characteristics by VeriStrat classification is given in Table 1. Only
histology showed significant correlation with VeriStrat classifica-
tion (adenocarcinoma vs other; Fisher’s exact test P¼ 0.02). It is of
note that recently presented results (Grigorieva et al, 2011)
indicate that, in contrast to previous results in non-BAC
adenocarcinoma and squamous cell carcinoma of the lung, no
significant separation in PFS was found between VeriStrat groups
in BAC lung cancer. Hence, in this analysis, BAC is listed
separately and not included in the adenocarcinoma subset, even
though the term ‘BAC’ is outdated and the histological subtype is
now considered as adenocarcinoma (Travis et al, 2011).
Table 1 Clinical characteristics of patients analysed by VeriStrat
No. of
Veristrat
Not available/
Characteristics patients Good Poor indeterminate P-valuea
Gender
Male 28 17 9 2 0.76
Female 22 16 6 0
Smoking history
Neverb 11 9 2 0 0.46
Ever 39 24 13 2
Performance score
0 30 22 7 1 0.22
1 20 11 8 1
Histology
Adenocarcinoma 34 27 7 0 0.02
Otherc 16 6 8 2
Stage
IIIB 13 7 5 1 0.48
IV 37 26 10 1
EGFR mutation status
Wild type 31 20 10 1 40.99d
Mutation 7 5 2 0
Not available 12 8 3 1
Abbreviation: EGFR¼ epidermal growth factor receptor. aP-value for Fisher’s exact
test for association between characteristic categories and VeriStrat classification
‘good’ and ‘poor’. bNever: less than 100 cigarettes in a lifetime. cOther: broncho-
alveolar carcinoma (BAC), squamous and large cell carcinoma. d‘Not available’
classification is not included in analysis.
VeriStrat and treatment with erlotinib and sorafenib
JL Kuiper et al
1821
& 2012 Cancer Research UK British Journal of Cancer (2012) 107(11), 1820 – 1825
C
li
n
ic
a
l
S
tu
d
ie
s
VeriStrat classification within 3 weeks of treatment
initiation
Changes in VeriStrat classification in the first weeks of treatment
were observed in a substantial proportion of patients. After 3
weeks, 41 samples were available and 35 patients had data at all
three time points (pre-treatment, weeks 1 and 3). One week after
commencement of therapy only 26 (60%) patients maintained their
pre-treatment VeriStrat classification, with 12 patients changing
from ‘good’ to ‘poor’ and 6 changing from ‘poor’ to ‘good’. About
45% of patients experienced further changes of classification at
week 3. As a result, out of 35 patients that had data at all three time
points, 46% maintained their classification throughout, 20%
changed at week 1 and reverted at week 3 (all these changes were
‘good’–‘poor’–‘good’), and 34% either changed at week 1 and
stayed changed or changed at week 3.
OS and PFS
Patients with pre-treatment classification of ‘good’ had statistically
significantly improved OS compared with those with pre-treatment
classification ‘poor’ (Figure 1). The HR for OS was 0.30 (95%
confidence interval (CI): 0.12–0.74), with log-rank P¼ 0.009.
Median OS was 13.7 months (95% CI: 12.0 months–undefined)
for the ‘good’ group and 5.6 months (95% CI: 1.6–7.6 months) for
the ‘poor’ group.
Patients with pre-treatment classification of ‘good’ had statis-
tically significantly improved PFS compared with patients with
‘poor’ classification (Figure 2). The HR between groups was 0.40
(95% CI: 0.17–0.94), with log-rank P¼ 0.035. Median PFS was 5.5
months (95% CI: 3.0–6.9 months) for the ‘good’ group and 2.7
months (95% CI: 1.4–5.6 months) for the ‘poor’ group.
In addition to VeriStrat classification, histology (large-cell and
squamous vs adenocarcinoma) was statistically significant in
univariate OS analysis. The median survival for adenocarcinoma
patients was 12.4 months (95% CI: 6.3 months-undefined) and 4.7
months (95% CI: 1.6–10.9 months) for patients with large cell or
squamous histology. In univariate PFS analysis, histology (adeno-
carcinoma vs large cell or squamous) and smoking history (never
vs ever) were significant as well (Table 2).
Given the relatively small sample size, with only 15 pre-
treatment samples classified as ‘poor’, meaningful multivariate
analysis was not possible. However, we could perform some
subgroup analysis. Figures 3A and B show OS and PFS for
adenocarcinoma patients by VeriStrat classification. The ‘good’
group had longer median OS and PFS (12.5 months and 5.5
months, respectively) than the ‘poor’ group (5.6 months and 2.7
months, respectively), although separation between groups did not
reach statistical significance for either comparison (log-rank
P¼ 0.21, HR¼ 0.45, 95% CI: 0.13–1.57 for OS and log-rank
P¼ 0.093, HR¼ 0.26, 95% CI: 0.06–1.25 for PFS). Examination of
the ever-smokers subgroup showed separation between ‘good’ and
‘poor’ groups that was significant in OS (P¼ 0.0074, HR¼ 0.27,
95% CI: 0.10–0.70) and trended to significance in PFS (P¼ 0.058,
HR¼ 0.43, 95% CI: 0.18–1.03) (Figures 3C and D). The small
number of patients with other histologies and who were never
smokers did not allow meaningful survival analysis in these
complementary subgroups.
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Figure 1 Kaplan–Meier plot of OS grouped by VeriStrat classification.
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Figure 2 Kaplan–Meier plot of PFS according to VeriStrat classification.
Table 2 Univariate analysis of OS and PFS for patients with pre-treatment serum samples classified as VeriStrat Good or VeriStrat Poor
OS PFS
Characteristics HR (95% CI) Log-rank P-value HR (95% CI) Log-rank P-value
VeriStrat classification ‘Poor’ vs ‘good’ 0.30 (0.12–0.74) 0.009 0.40 (0.17–0.94) 0.035
Smoking Nevera vs ever 1.61 (0.71–3.69) 0.257 2.12 (1.06–4.25) 0.034
Histology Adenocarcinoma vs otherb 2.81 (1.05–7.51) 0.040 2.48 (1.04–5.91) 0.041
Gender Female vs male 1.15 (0.55–2.39) 0.714 1.25 (0.66–2.39) 0.494
PS PS 0 vs PS 1 2.06 (0.94–4.49) 0.070 1.67 (0.86–3.25) 0.133
EGFR mutation Wild-type vs EGFR mutation 0.57 (0.21–1.51) 0.257 0.65 (0.28–1.52) 0.322
Stage IIIB vs IV 0.64 (0.26–1.59) 0.342 0.57 (0.26–1.27) 0.171
Abbreviations: CI¼ confidence interval; EGFR¼ epidermal growth factor receptor; HR¼ hazard ratios; OS¼ overall survival; PFS¼ progression-free survival; PS¼ performance
score. aNever: less than 100 cigarettes in a lifetime. bOther: broncho-alveolar carcinoma, squamous and large cell carcinoma.
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Carrying out survival analysis with the PFS data (relative to same
starting point as for the pre-treatment analysis) using the VeriStrat
classifications obtained from the samples collected at weeks 1 and 3
yields no statistically significant separation between groups (Figure 4).
For week 1 classification, the analysis produces HR¼ 0.61 (95% CI:
0.31–1.23) and log-rank value P¼ 0.17, whereas for week 3 classifica-
tion, the HR is 0.97 (95% CI: 0.41–2.30) and log-rank P-value is 0.94.
Response rates
Five patients were not evaluable for response: four patients
discontinued treatment before the week 6 CT scan and one patient
developed a large cavity in the primary tumour superimposed by
infection. Of these five patients, three were classified as ‘poor’ and
two were classified as ‘good’. Considering response rates at 6 weeks
after commencing treatment by pre-treatment VeriStrat classifica-
tion, disease control was maintained in 84% of the ‘good’ group
and in 75% of the ‘poor’ group, this difference was not statistically
significant (Fisher’s exact test P-value¼ 0.66) (Table 3). In 26% of
the ‘good’ group, an objective response was measured compared
with a response rate of 25% in the ‘poor’ group, the difference not
being significant (Fisher’s exact test P-value 40.99).
DISCUSSION
Selection of patients most likely to benefit from specific therapies
remains a challenging task in the treatment of NSCLC. This study
demonstrates the capacity of the VeriStrat test to stratify patients
with advanced stage NSCLC after treatment with erlotinib and
sorafenib in terms of OS and PFS.
VeriStrat was developed from pre-treatment sera of patients
treated with gefitinib and subsequently proved able to identify
patients likely to have ‘poor’ or ‘good’ outcomes after EGFR-TKI
treatment (Taguchi et al, 2007). A retrospective analysis on a
subset of patients from the BR.21 trial (Shepherd et al, 2005)
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Figure 3 Subgroup analyses by VeriStrat classification. (A) OS for adenocarcinoma patients, (B) PFS for adenocarcinoma patients, (C) OS for
ever-smokers and (D) PFS for ever-smokers.
100 VeriStrat Good
VeriStrat Poor
VeriStrat Good
VeriStrat Poor
80
Pe
rc
e
n
ta
ge
Pe
rc
e
n
ta
ge60
40
20
At risk:
A B
VeriStrat Good  19 9 6 2 0 13 6 2 0
8 2 1 0 4 2 1 0VeriStrat Good  25
At risk:
VeriStrat Good  19
VeriStrat Good  25
PFS (months) PFS (months)
0
100
80
60
40
20
0
0 5 10 15 20 0 5 10 15 20
Figure 4 Kaplan–Meier plot of PFS (measured relative to original starting point) grouped by weeks (A) 1 and (B) 3 VeriStrat classification.
VeriStrat and treatment with erlotinib and sorafenib
JL Kuiper et al
1823
& 2012 Cancer Research UK British Journal of Cancer (2012) 107(11), 1820 – 1825
C
li
n
ic
a
l
S
tu
d
ie
s
showed a significant prolongation of OS in the ‘good’ group after
treatment with erlotinib, whereas there was no significant benefit
for the ‘poor’ group. At the same time, the significant prognostic
power of VeriStrat, that is, separation of VeriStrat groups in OS
and PFS in the placebo arm, was also demonstrated (Carbone et al,
2010a). In addition, VeriStrat has been able to stratify outcomes of
patients treated with a combination of TKIs and VEGF inhibitors
(erlotinib and bevacizumab) (Akerley et al, 2010; Carbone et al,
2010b; Gautschi et al, 2012). As erlotinib in combination with
newer oral VEGF receptor inhibitors such as sorafenib may have
clinically relevant antitumour activity (Lind et al, 2010), it is of
interest that in this cohort of patients treated with erlotinib and
sorafenib, VeriStrat has again demonstrated its potential to
identify patients likely to have good and poor outcomes.
The study presented has several limitations, common to many
retrospective analyses of phase II studies and related to the small
number of the samples. Thus, multivariate analysis that would have
given an estimation of the significance of VeriStrat classification in
the presence of possible confounding factors was not feasible.
Previous analyses in larger retrospective studies have shown that
VeriStrat classification remains a significant factor for outcome in
advanced NSCLC patients (Amann et al, 2010; Carbone et al, 2010a),
although, these studies involved different treatment regimens.
However, although the size of the study did not allow meaningful
multivariate analysis, consistent behaviour was found in adenocar-
cinoma and ever-smoker subgroups. Despite that, the small group
sizes did not give sufficient power to always expect significant
differences and these results should be treated with caution.
This study found a significant correlation between VeriStrat
classification and histology, a finding that has been observed in
previous studies. In larger studies, multivariate analysis was
possible and it has been shown that VeriStrat remains a significant
predictor even when adjusted for this and other possible
confounding factors (Taguchi et al, 2007; Carbone et al, 2010a).
In the original development study (Taguchi et al, 2007) no
statistically significant separation between VeriStrat groups was
found in patients treated with surgery or second-line chemotherapy.
VeriStrat Poor patients may have an advantage when they are
treated with chemotherapy instead of EGFR-TKIs, in contrast to the
VeriStrat Good patients who may be likely to benefit from treatment
with targeted therapy (Gregorc, 2009). Two ongoing prospective
phase III trials are designed to further validate the role of VeriStrat
as a test for treatment optimisation in NSCLC; both trials use
VeriStrat classification as a stratification factor. PROSE is a
randomised phase III study of second-line erlotinib vs chemother-
apy in patients with inoperable NSCLC stratified by VeriStrat
classification (Sorlini et al, 2011). The EMPHASIS trial (European
Thoracic Oncology Platform) compares treatment of erlotinib vs
docetaxel in patients with squamous histology in patients who failed
first-line chemotherapy.
Recently, the potential of VeriStrat for follow-up during
treatment was described (Lazzari et al, 2012). The risk of
progression with new lesions in patients that changed classification
from ‘good’ pre-treatment to ‘poor’ near progression when treated
with gefitinib was significantly higher than in the rest of the study
population. Although further prospective research on this topic is
necessary, it illustrates the potential of VeriStrat as a longitudinal
marker. In our study, serum samples taken after 1 and 3 weeks of
treatment were not related to outcome and were much more
variable than in the previous study, although 66% of patients did
keep or return to their pre-treatment classification 3 weeks after
treatment initiation. The differences in the stability of the
classification are probably related to the duration of the intervals
between sample collections: in the former study they were much
longer (pre-treatment, after 1 month of therapy, every 2 months
thereafter until progression) than in our trial. Hence, it is possible
that the initiation of therapy has a short-term role in changing the
classification of some patients, who then return to their original
classification on a longer time scale. Also, the previous study
involved treatment with gefitinib monotherapy and this study
involves dual EGFR/VEGF inhibition, which may be a factor as
well. The biological meaning of these short-term changes is unclear
and needs further investigation.
The proteins that make up the VeriStrat proteomic signature
have not yet been conclusively identified. A recent publication
(Milan et al, 2012) confirmed our earlier (unpublished) results that
four out of the eight peaks of the VeriStrat signature contain
several forms of SAA1. However, while numerous studies have
shown elevated levels of SAA1 in various malignancies as well as
other diseases (Biran et al, 1986; Kokubun et al, 2005; Dowling
et al, 2012), attempts to use its direct measurement did not lead to
the development of any clinically useful test. We do not know yet
the identity of other proteins constituting the signature, as well as
whether proteins identified are causing the effect or are just highly
correlated with some other proteins relevant to the mechanism of
action of the test (Venet et al, 2011). The differential biological
activity of VeriStrat Good and Poor serum was shown in cell line
experiments, which have demonstrated that it is possible to
decrease the sensitivity of some lung cancer cells to EGFR
inhibitors by incubating them in media containing VeriStrat Poor
serum (Hunsucker et al, 2011). We hypothesise that the signature
is associated with specific tumour–host interactions, which lead to
the differential responses to various treatments between VeriStrat
groups. It is interesting to note that several studies (Amann et al,
2010; Chung et al, 2010; Lazzari et al, 2012) and the BR.21
retrospective analysis (Carbone et al, 2010a) have evaluated the
relation between VeriStrat classification and EGFR mutations, and
no significant correlations have been found. We think that worse
outcome observed in VeriStrat Poor patients treated with sorafenib
and erlotinib may result from a complex interaction of tumour
cells and tumour microenvironment.
In conclusion, this study demonstrates that VeriStrat, a serum
proteomic test based on MALDI-MS of pre-treatment serum
samples, can separate chemotherapy-naive advanced NSCLC
patients treated with the erlotinib and sorafenib combination in
groups with statistically different outcomes in terms of PFS and
OS. The results need to be confirmed in a larger trial population.
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Table 3 Response rates
VeriStrat
Response Good Poor Missing/indeterminate P-value
Best response
PR (N¼ 14) 9 3 2 0.80
SD (N¼ 23) 17 6 0
PD (N¼ 8) 5 3 0
Obj. response
PR (N¼ 14) 9 3 2 1.00
SDþ PD (N¼ 31) 22 9 0
Disease control
PRþ SD (N¼ 37) 26 9 2 0.66
PD (N¼ 8) 5 3 0
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